USANA Health Sciences, Inc. - 10-K Summary (Fiscal Year Ended Jan 3, 2009)
Business Context and Reporting Period
This report covers the fiscal year ended January 3, 2009 (a 53-week year). USANA Health Sciences, Inc. is a Utah-based corporation that develops, manufactures, and distributes high-quality nutritional and personal care products through a global network marketing system. The company operates in two primary geographic regions: North America (60.6% of sales) and Asia Pacific (39.4% of sales). As of the reporting date, the company had 198,000 active Associates and 71,000 active Preferred Customers worldwide.
Key Financial Metrics
| Metric | 2008 (Restated) | 2007 (Restated) | 2006 (Restated) |
|---|---|---|---|
| Net Sales | $429.0 million | $423.1 million | $365.2 million |
| Gross Profit | $340.1 million (79.3% margin) | $335.3 million (79.2% margin) | $285.3 million (78.1% margin) |
| Net Earnings | $29.9 million | $45.0 million | $40.4 million |
| Diluted EPS | $1.85 | $2.62 | $2.16 |
| Operating Cash Flow | $46.0 million | $58.2 million | $61.3 million |
| Line of Credit Balance | $35.0 million | $28.0 million | $0 |
| Working Capital | ($1.9 million) | $0.1 million | $16.3 million |
Note: Financial data for 2006 and 2007 has been restated to correct errors related to income taxes payable and equity-based compensation.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 1.4% to $429.0 million, driven by growth in East Asia (up 24.5%) and an extra week of sales in the 53-week fiscal year. This offset a 5.0% decline in U.S. sales.
- Profitability Decline: Net earnings decreased 34.4% to $29.9 million. This was primarily due to a $7.0 million unanticipated arbitration award, increased selling, general, and administrative (SG&A) expenses, and unfavorable currency exchange impacts in Q4.
- Expense Increases: SG&A expenses rose to 26.5% of net sales (from 22.3% in 2007). Excluding the $7.0 million arbitration award, SG&A would have been 24.9% of sales. Associate incentives increased to 41.6% of net sales.
- Liquidity Position: Working capital turned negative to ($1.9 million) due to the accrual of the arbitration award and increased inventory levels. Cash and cash equivalents remained stable at $13.3 million.
Guidance, Outlook, and Risks
- Management Commentary: Management attributes the Q4 sales slowdown to lingering negative publicity from 2007 and deteriorating U.S. economic conditions. However, new Compensation Plan enhancements introduced in Q3 2008 (Elite Bonus and Matching Bonus) are expected to drive growth in 2009.
- Unusual Items: The company settled a pending IRS audit in February 2009, resulting in a $4.4 million tax liability and $0.8 million in interest. Additionally, a $7.0 million arbitration award was accrued but not yet paid as of year-end.
- Liquidity Outlook: The company anticipates unusual cash payments of approximately $15 million in the first six months of 2009 (covering the arbitration award and IRS settlement). Management expects to cover these needs using current cash, operating cash flow, and the $40 million line of credit, potentially delaying capital projects or share repurchases.
- Risks: Key risks include dependence on an independent sales force, regulatory scrutiny of network marketing and product claims (FTC/FDA), currency exchange fluctuations, and the potential for adverse publicity.
Investor Verification Checklist
- Restatement Impact: Verify the specific adjustments made to 2006 and 2007 financials regarding income taxes and equity compensation to ensure accurate trend analysis.
- Arbitration Settlement: Confirm the status of the $7.0 million arbitration award payment and any potential for further legal challenges or similar claims.
- IRS Settlement: Review the details of the $5.2 million total tax settlement (taxes + interest) and its impact on future effective tax rates.
- Associate Trends: Monitor the growth rate of active Associates versus Preferred Customers, noting the decline in Preferred Customers in North America.
- Currency Exposure: Assess the impact of a strengthening U.S. dollar on future international sales, given that 62.4% of sales are generated outside the U.S.